CN109310638A - 缬草组合物和相关方法 - Google Patents

缬草组合物和相关方法 Download PDF

Info

Publication number
CN109310638A
CN109310638A CN201780027996.7A CN201780027996A CN109310638A CN 109310638 A CN109310638 A CN 109310638A CN 201780027996 A CN201780027996 A CN 201780027996A CN 109310638 A CN109310638 A CN 109310638A
Authority
CN
China
Prior art keywords
dosage form
valerian
pharmaceutical dosage
polymer
acidulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780027996.7A
Other languages
English (en)
Chinese (zh)
Inventor
赛义德·M·沙阿
克里斯多夫·迪奥里奥
丹尼尔·哈森
弗瑞德·哈森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Physicians Seal LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal LLC filed Critical Physicians Seal LLC
Priority to CN202311459688.5A priority Critical patent/CN117482062A/zh
Publication of CN109310638A publication Critical patent/CN109310638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201780027996.7A 2016-05-06 2017-05-04 缬草组合物和相关方法 Pending CN109310638A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311459688.5A CN117482062A (zh) 2016-05-06 2017-05-04 缬草组合物和相关方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332728P 2016-05-06 2016-05-06
US62/332,728 2016-05-06
PCT/US2017/031046 WO2017192843A1 (en) 2016-05-06 2017-05-04 Valerian composition and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311459688.5A Division CN117482062A (zh) 2016-05-06 2017-05-04 缬草组合物和相关方法

Publications (1)

Publication Number Publication Date
CN109310638A true CN109310638A (zh) 2019-02-05

Family

ID=60203773

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780027996.7A Pending CN109310638A (zh) 2016-05-06 2017-05-04 缬草组合物和相关方法
CN202311459688.5A Pending CN117482062A (zh) 2016-05-06 2017-05-04 缬草组合物和相关方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311459688.5A Pending CN117482062A (zh) 2016-05-06 2017-05-04 缬草组合物和相关方法

Country Status (10)

Country Link
US (4) US10342873B2 (https=)
EP (1) EP3452020A4 (https=)
JP (2) JP7576905B2 (https=)
KR (1) KR20190008265A (https=)
CN (2) CN109310638A (https=)
AU (1) AU2017260019A1 (https=)
CA (1) CA3023305C (https=)
MX (1) MX2018013569A (https=)
RU (1) RU2018142019A (https=)
WO (1) WO2017192843A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022012199A2 (pt) * 2020-01-17 2022-09-13 Nestle Sa Forma de dosagem com péletes de melatonina de liberação sustentada
IT202200013576A1 (it) * 2022-06-27 2023-12-27 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato a rilascio differenziato di melatonina e principi attivi

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850212A (zh) * 2006-02-28 2006-10-25 潮州市强基制药厂 一种缬草油液体硬胶囊及其制备方法
US20070196348A1 (en) * 2006-02-23 2007-08-23 Gardiner Paul T Compositions and methods for the induction and maintenance of quality sleep
CN102058630A (zh) * 2010-12-16 2011-05-18 苏州大学 一种镇静安神的缬草制剂及其制备方法
CN102114060A (zh) * 2011-02-22 2011-07-06 都晓伟 黑水缬草提取物及其制备方法和应用
WO2015120006A1 (en) * 2014-02-06 2015-08-13 Sequential Medicine Limited Composition and method for aiding sleep
US20160067186A1 (en) * 2011-01-28 2016-03-10 Zx Pharma, Llc Controlled-Release Melatonin Compositions and Related Methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699075A1 (fr) * 1992-12-11 1994-06-17 Rech Sarl Ab Préparation médicinale à libération programmable dans le temps notamment à base de plantes.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2727315A1 (fr) 1994-11-30 1996-05-31 Cooperative Agricole Laitiere Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
WO2001007063A1 (en) 1999-07-21 2001-02-01 Ancile Pharmaceuticals Process for the extraction of valerian root
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
EP1465600B1 (en) * 2001-12-20 2007-03-07 Alpex Pharma SA Particulate compositions comprising a lipophilic liquid
ATE477809T1 (de) * 2004-04-06 2010-09-15 Taiyokagaku Co Ltd Verwendung einer kombination von theanin und serotonin gegen schlafstörung
ATE516019T1 (de) 2004-05-11 2011-07-15 Egalet Ltd Quellbare dosierform mit gellan-gummit
WO2006040596A2 (en) 2004-10-11 2006-04-20 Nasaleze Ppm Limited Compositions for intranasal administration
US8821926B2 (en) 2005-06-22 2014-09-02 Takeda Pharmaceutical Company Limited Tablet containing hardly soluble active ingredient
BRPI0719442A2 (pt) 2006-09-27 2013-12-03 Finzelberg Gmbh & Co Kg Processo para a preparação de um extrato de valeriana
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20090197974A1 (en) * 2008-02-05 2009-08-06 Khaleeq Ahmed Natural dietary supplement tablet
US8809395B2 (en) 2009-01-23 2014-08-19 Valericon Gmbh Methods for making valerenic acid derivatives and their use
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN102370833B (zh) * 2010-08-17 2014-03-26 北京亚东生物制药有限公司 一种解表祛暑的泡腾剂及其制备方法和用途
CN102247443A (zh) * 2010-12-23 2011-11-23 祝凤仪 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法
UY33869A (es) 2011-01-17 2012-08-31 Takeda Pharmaceutical Comprimido dispersable por vía oral
JP2013053144A (ja) * 2011-08-09 2013-03-21 Daiichi Sankyo Healthcare Co Ltd 鎮静剤組成物
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3120969C (en) 2012-01-26 2026-01-13 Foodberry, Inc. Enclosing materials in natural transport systems
CA2928777A1 (en) 2012-11-09 2014-06-05 Abattis Bioceuticals Corp. Nitric oxide increasing nutritional supplements and methods
US20140271890A1 (en) 2013-03-14 2014-09-18 Thaer Ahmad Controlled-release pharmaceutical composition
ES2706152T3 (es) * 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico
PL231923B1 (pl) 2013-10-28 2019-04-30 Proteon Pharmaceuticals Spolka Akcyjna Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania
RU2535020C1 (ru) 2014-01-23 2014-12-10 Карпов Алексей Николаевич Фармацевтическая композиция седативного и спазмолитического действия
JP6730935B2 (ja) * 2014-05-05 2020-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 迅速溶解性顆粒
ES2597784T3 (es) 2014-07-14 2017-01-23 Dr. Willmar Schwabe Gmbh & Co. Kg Combinación de extracto de raíz de valeriana y aceite de lavanda para utilizar en el tratamiento de trastornos del sueño

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196348A1 (en) * 2006-02-23 2007-08-23 Gardiner Paul T Compositions and methods for the induction and maintenance of quality sleep
CN1850212A (zh) * 2006-02-28 2006-10-25 潮州市强基制药厂 一种缬草油液体硬胶囊及其制备方法
CN102058630A (zh) * 2010-12-16 2011-05-18 苏州大学 一种镇静安神的缬草制剂及其制备方法
US20160067186A1 (en) * 2011-01-28 2016-03-10 Zx Pharma, Llc Controlled-Release Melatonin Compositions and Related Methods
CN102114060A (zh) * 2011-02-22 2011-07-06 都晓伟 黑水缬草提取物及其制备方法和应用
WO2015120006A1 (en) * 2014-02-06 2015-08-13 Sequential Medicine Limited Composition and method for aiding sleep

Also Published As

Publication number Publication date
JP2019514977A (ja) 2019-06-06
US10342873B2 (en) 2019-07-09
US20190321475A1 (en) 2019-10-24
CA3023305C (en) 2024-07-02
RU2018142019A (ru) 2020-06-08
MX2018013569A (es) 2019-03-14
US11141484B2 (en) 2021-10-12
EP3452020A1 (en) 2019-03-13
BR112018072795A2 (pt) 2019-04-30
RU2018142019A3 (https=) 2020-09-16
AU2017260019A1 (en) 2018-11-22
CN117482062A (zh) 2024-02-02
EP3452020A4 (en) 2020-02-19
US20190328881A1 (en) 2019-10-31
JP7577090B2 (ja) 2024-11-01
US11701425B2 (en) 2023-07-18
US20170319697A1 (en) 2017-11-09
US11141485B2 (en) 2021-10-12
WO2017192843A1 (en) 2017-11-09
KR20190008265A (ko) 2019-01-23
CA3023305A1 (en) 2017-11-09
JP7576905B2 (ja) 2024-11-01
US20210401990A1 (en) 2021-12-30
JP2022116251A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
Fini et al. Fast dispersible/slow releasing ibuprofen tablets
US9474721B2 (en) Abuse-resistant formulations
US6426091B1 (en) Sustained-release theophylline tablet
MXPA04009968A (es) Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
KR20040004638A (ko) 의약 조성물
AU2008347949A1 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
CZ20023470A3 (cs) Farmaceutický prostředek
RS53087B (sr) Čvrste farmaceutske kompozicije stalnog sastava koje sadrže irbesartan i amlodipin, njihovo dobijanje i terapijska primena
Tehseen et al. Design and characterization of twice daily mini-tablets formulation of pregabalin
JP7577090B2 (ja) バレリアン組成物及び関連方法
US20040037880A1 (en) Extended release formulation of divalproex sodium
Olah et al. Evaluating superdisintegrants for their performance in orally disintegrating tablets containing lysozyme enzyme
EP2538924A2 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
TWI630911B (zh) 包含異菸鹼醯胺（ｉｓｏｎｉａｚｉｄ）顆粒及利福噴丁（ｒｉｆａｐｅｎｔｉｎｅ）顆粒之可分散錠劑型態的抗肺結核穩定醫藥組合物及其製備方法
HUE031792T2 (en) New alfentanil composition for the treatment of acute pain
EP1539113A2 (en) Modified release ketoprofen dosage form
Rashad et al. Chronological delivery of antihypertensive drugs in bilayered core-in-cup buccoadhesive tablets: In vitro and in vivo evaluation
JP7764378B2 (ja) フィルムコーティング錠剤
AY et al. Predictable pulsatile release of candesartan cilexetil for chronotherapeutics of hypertension
Samy et al. Formulation and evaluation of Dicyclomine hydrochloride matrix tablets for colon specific drug delivery
Seshadri et al. Formulation and evaluation of pulsatile delivery system of zolpidem tartrate
BR122021015452B1 (pt) Uso de valeriana e de um agente acidificante na fabricação de uma composição para tratar dor, insônia, ansiedade, deficiência de melatonina, distúrbio de sono e/ou um distúrbio de ritmo circadiano e método para produção de uma forma de dosagem farmacêutica de valeriana estável em armazenamento
BR112018072795B1 (pt) Comprimido ou cápsula consistindo em valeriana dentro de uma matriz polimérica acidificada
Lala et al. Selection of a suitable polymeric matrix for chrono-therapeutic drug delivery: a comparative study
Gupta FORMULATION AND EVALUATION OF CANDESARTAN CILEXETIL POROUS TABLETS BY SUBLIMATION TECHNIQUE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210610

Address after: Vevey

Applicant after: Societe des Produits Nestle S.A.

Address before: Boca Raton, Florida, USA

Applicant before: PHYSICIAN'S SEAL, LLC

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190205